549 related articles for article (PubMed ID: 26803236)
1. Optimal duration of dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes: The SECURITY (Second-Generation Drug-Eluting Stent Implantation Followed By Six- Versus Twelve-Month Dual Antiplatelet Therapy)-diabetes substudy.
Tarantini G; Nai Fovino L; Tellaroli P; Chieffo A; Barioli A; Menozzi A; Frasheri A; Garbo R; Masotti-Centol M; Salvatella N; Dominguez JF; Steffanon L; Presbitero P; Pucci E; Fraccaro C; Mauri J; Giustino G; Sardella G; Colombo A
Int J Cardiol; 2016 Mar; 207():168-76. PubMed ID: 26803236
[TBL] [Abstract][Full Text] [Related]
2. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial.
Colombo A; Chieffo A; Frasheri A; Garbo R; Masotti-Centol M; Salvatella N; Oteo Dominguez JF; Steffanon L; Tarantini G; Presbitero P; Menozzi A; Pucci E; Mauri J; Cesana BM; Giustino G; Sardella G
J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2086-97. PubMed ID: 25236346
[TBL] [Abstract][Full Text] [Related]
3. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
Hahn JY; Song YB; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Kim J; Choi KH; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Gwon HC;
Lancet; 2018 Mar; 391(10127):1274-1284. PubMed ID: 29544699
[TBL] [Abstract][Full Text] [Related]
4. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
[TBL] [Abstract][Full Text] [Related]
5. Duration of dual antiplatelet therapy after various drug-eluting stent implantation.
Sharma A; Sharma SK; Vallakati A; Garg A; Lavie CJ; Mukherjee D; Marmur JD
Int J Cardiol; 2016 Jul; 215():157-66. PubMed ID: 27116326
[TBL] [Abstract][Full Text] [Related]
6. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
[TBL] [Abstract][Full Text] [Related]
7. Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy.
Lee BK; Kim JS; Lee OH; Min PK; Yoon YW; Hong BK; Shin DH; Kang TS; Kim BO; Cho DK; Jeon DW; Woo SI; Choi S; Kim YH; Kang WC; Kim S; Kim BK; Hong MK; Jang Y; Kwon HM
EuroIntervention; 2018 Mar; 13(16):1923-1930. PubMed ID: 29104179
[TBL] [Abstract][Full Text] [Related]
8. 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
Hong SJ; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Her AY; Kim YH; Jang Y; Hong MK;
JACC Cardiovasc Interv; 2016 Jul; 9(14):1438-46. PubMed ID: 27212028
[TBL] [Abstract][Full Text] [Related]
9. A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the "DAPT-STEMI trial".
Kedhi E; Fabris E; van der Ent M; Kennedy MW; Buszman P; von Birgelen C; Cook S; Wedel H; Zijlstra F
Am Heart J; 2017 Jun; 188():11-17. PubMed ID: 28577666
[TBL] [Abstract][Full Text] [Related]
10. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).
Kim BK; Hong MK; Shin DH; Nam CM; Kim JS; Ko YG; Choi D; Kang TS; Park BE; Kang WC; Lee SH; Yoon JH; Hong BK; Kwon HM; Jang Y;
J Am Coll Cardiol; 2012 Oct; 60(15):1340-8. PubMed ID: 22999717
[TBL] [Abstract][Full Text] [Related]
11. Dual Antiplatelet Therapy for 6 Months vs 12 Months After New-generation Drug-eluting Stent Implantation: Matched Analysis of ESTROFA-DAPT and ESTROFA-2.
de la Torre Hernández JM; Oteo Domínguez JF; Hernández F; García Camarero T; Abdul-Jawad Altisent O; Rivero Crespo F; Cascón JD; Zavala G; Gimeno F; Arrebola Moreno AL; Andraka L; Gómez Menchero A; Bosa F; Carrillo X; Sánchez Recalde Á; Alfonso F; Pérez de Prado A; López Palop R; Sanchis J; Diarte de Miguel JA; Jiménez Navarro M; Muñoz L; Ramírez Moreno A; Tizón Marcos H;
Rev Esp Cardiol (Engl Ed); 2015 Oct; 68(10):838-45. PubMed ID: 26072146
[TBL] [Abstract][Full Text] [Related]
12. Duration of dual antiplatelet therapy after myocardial infarction: Insights from a pooled database of the SMART-DATE and DAPT-STEMI trials.
Kedhi E; Delewi R; Fabris E; De Luca G; Hermanides RS; van den Ent M; Buszman P; Zijlstra F; Song YB; Gwon HC; Hahn JY
Atherosclerosis; 2020 Dec; 315():55-61. PubMed ID: 33227548
[TBL] [Abstract][Full Text] [Related]
13. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
; Bittl JA; Baber U; Bradley SM; Wijeysundera DN
Circulation; 2016 Sep; 134(10):e156-78. PubMed ID: 27026019
[TBL] [Abstract][Full Text] [Related]
14. Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial.
Han Y; Xu B; Xu K; Guan C; Jing Q; Zheng Q; Li X; Zhao X; Wang H; Zhao X; Li X; Yu P; Zang H; Wang Z; Cao X; Zhang J; Pang W; Li J; Yang Y; Dangas GD
Circ Cardiovasc Interv; 2016 Feb; 9(2):e003145. PubMed ID: 26858080
[TBL] [Abstract][Full Text] [Related]
15. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Bittl JA; Baber U; Bradley SM; Wijeysundera DN
J Am Coll Cardiol; 2016 Sep; 68(10):1116-39. PubMed ID: 27036919
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
Lee SY; Hong MK; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Kim HS; Valgimigli M; Palmerini T; Stone GW
Clin Res Cardiol; 2017 Mar; 106(3):165-173. PubMed ID: 27631821
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of dual antiplatelet therapy use in patients following everolimus-eluting stent implantation: insights from the SEEDS study.
Zhang YJ; Zhao YL; Xu B; Han YL; Li B; Liu Q; Su X; Pang S; Lu SZ; Guo XF; Yang YJ
Chin Med J (Engl); 2015 Mar; 128(6):714-20. PubMed ID: 25758261
[TBL] [Abstract][Full Text] [Related]
18. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial.
Natsuaki M; Morimoto T; Yamamoto E; Shiomi H; Furukawa Y; Abe M; Nakao K; Ishikawa T; Kawai K; Yunoki K; Shimizu S; Akao M; Miki S; Yamamoto M; Okada H; Hoshino K; Kadota K; Morino Y; Igarashi K; Tanabe K; Kozuma K; Kimura T
Cardiovasc Interv Ther; 2016 Jul; 31(3):196-209. PubMed ID: 26518420
[TBL] [Abstract][Full Text] [Related]
19. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
20. Impact of six versus 12 months of dual antiplatelet therapy in patients with drug-eluting stent implantation after risk stratification with the residual SYNTAX score: Results from a secondary analysis of the I-LOVE-IT 2 trial.
Qiu M; Li Y; Li J; Xu K; Jing Q; Dong S; Jin Z; Zhao P; Xu B; Han Y
Catheter Cardiovasc Interv; 2017 Mar; 89(S1):565-573. PubMed ID: 28211603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
